Cocrystal Pharma Reports Phase 1 Results With Oral, Broad-Acting Antiviral Drug CDI-988 For Prophylaxis And Treatment Of Norovirus, Coronaviruses And Other Viral Infections; Data Show Favorable Safety And Tolerability With Dosing Up To 800 Mg For 10...
Cocrystal Pharma Reports Phase 1 Results With Oral, Broad-Acting Antiviral Drug CDI-988 For Prophylaxis And Treatment Of Norovirus, Coronaviruses And Other Viral Infections; Data Show Favorable Safety And Tolerability With Dosing Up To 800 Mg For 10...
Cocrystal Pharma Reports Phase 1 Results With Oral, Broad-Acting Antiviral Drug CDI-988 For Prophylaxis And Treatment Of Norovirus, Coronaviruses And Other Viral Infections; Data Show Favorable Safety And Tolerability With Dosing Up To 800 Mg For 10 Days; Plans To Initiate Human Challenge Study In 2025 In Norovirus-infected Subjects
Cocrystal Pharma報告了口服廣泛作用抗病毒藥物CDI-988在預防和治療諾如病毒、冠狀病毒及其他病毒感染方面的第一階段結果；數據顯示，在每天最高達800毫克的劑量下，安全性和耐受性良好，持續10天；計劃在2025年在諾如病毒感染者中啓動人類挑戰研究。
- Data show favorable safety and tolerability with dosing up to 800 mg for 10 days
- Plans to initiate human challenge study in 2025 in norovirus-infected subjects
- 數據顯示，在每天最高達800毫克的劑量下，安全性和耐受性良好，持續10天。
- 計劃在2025年在諾如病毒感染者中啓動人類挑戰研究。
BOTHELL, Wash., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ:COCP) ("Cocrystal" or the "Company") announces favorable safety and tolerability results at dosing up to 800 mg per day for 10 consecutive days from the multiple-ascending dose (MAD) portion of the ongoing Phase 1 study with its oral protease inhibitor CDI-988, the first pan-viral drug candidate in development as an orally administered treatment of norovirus and coronavirus infections. The Company also announces that an additional cohort with a higher dose of 1,200 mg and a shorter treatment duration of five consecutive days will be conducted to further assess CDI-988's safety, tolerability and pharmacokinetics.
華盛頓州博塞爾，2025年1月8日（全球新聞熱線）——Cocrystal Pharma, Inc.（納斯達克：COCP）（"Cocrystal"或"公司"）宣佈在進行中的第一階段研究中，口服蛋白酶抑制劑CDI-988的遞增多次劑量（MAD）部分中，日劑量高達800毫克的安全性和耐受性結果良好，持續10天。該公司還宣佈，將進行一個額外的隊列，給予更高劑量的1200毫克和更短的治療持續時間（連續五天），以進一步評估CDI-988的安全性、耐受性和藥代動力學。
